Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.

Leukemia. 2018 Mar 27. doi: 10.1038/s41375-018-0117-x. [Epub ahead of print] Review.

2.

Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R.

Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2.

3.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

4.

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R.

Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Review.

5.

Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.

Kinslechner K, Schörghofer D, Schütz B, Vallianou M, Wingelhofer B, Mikulits W, Röhrl C, Hengstschläger M, Moriggl R, Stangl H, Mikula M.

Mol Cancer Res. 2018 Jan;16(1):135-146. doi: 10.1158/1541-7786.MCR-17-0292. Epub 2017 Oct 3.

6.

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E.

Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017 Apr 11.

7.

O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

Freund P, Kerenyi MA, Hager M, Wagner T, Wingelhofer B, Pham HTT, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer OH, Groner B, Moriggl R.

Leukemia. 2017 Oct;31(10):2132-2142. doi: 10.1038/leu.2017.4. Epub 2017 Jan 11.

8.

Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines.

Wingelhofer B, Kreis K, Mairinger S, Muchitsch V, Stanek J, Wanek T, Langer O, Kuntner C.

Appl Radiat Isot. 2016 Dec;118:67-72. doi: 10.1016/j.apradiso.2016.08.026. Epub 2016 Sep 1.

PMID:
27619946
9.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B.

Carcinogenesis. 2014 Oct;35(10):2331-8. doi: 10.1093/carcin/bgu151. Epub 2014 Jul 16.

PMID:
25031272

Supplemental Content

Loading ...
Support Center